argenx Stock
argenx SE
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Netherlands
- CEO
- Karen Massey
- Employees
- 1,863
- Market cap
- $50.7 B
- IPO
- 18/05/2017
Based in the Netherlands, argenx SE is a healthcare/biotechnology player specializing in the development of innovative therapies for autoimmune diseases. A core component of ARGX's business operations is the continued development of efgartigimod to treat various indications, including myasthenia gravis and…
AI-generated company profile based on the figures on this page, last updated on 01/10/2026. Not investment advice.
argenx stock: price history
1D
-3.2%
1W
-0.7%
1M
-16.8%
6M
-3.5%
YTD
-2.6%
1Y
-2.2%
2Y
+51.5%
5Y
+178.9%
10Y
–
Next earnings date
Next earnings date
04/03/2027 (in 138 days)
Volatility around earnings
~9% weaker price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 16/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
argenx stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Average business model without a clear megatrend link or with mixed signals.
argenx SE is a specialized biotechnology company headquartered in the Netherlands that focuses on the development and commercialization of innovative therapies for autoimmune diseases. The business model is based on research and the distribution of proprietary pharmaceutical products such as VYVGART to global markets, with a substantial portion of revenue generated in the United States. In addition to developing its own active pharmaceutical ingredients, the company leverages strategic partnerships and licensing agreements with partners from the pharmaceutical industry to advance its research pipeline. Through its specialization in complex inflammatory conditions, the company maintains a strong market position in its indication areas by virtue of its patent-protected products.
- Revenue model
- Transactional
- Recurring revenue
- None
- Pricing power
- Strong
- Moat
- None
- Moat type
- None
- Capital intensity
- High
- Customer concentration
- Unknown
Suppliers & customers in our universe
IQVIA Holdings Inc.DescriptionAsk the agents about argenx
Analyst assessment of argenx
PRICE TARGET LOW
US$823.00
CONSENSUS
US$1,138.60
MEDIAN
US$1,140.00
PRICE TARGET HIGH
US$1,400.00
1
STRONG BUY
31
BUY
4
HOLD
0
SELL
0
STRONG SELL
36
TOTAL · Buy
As of: 14/10/2026
argenx stock metrics
P/E
29.64
P/B
6.04
EV/EBITDA
29.86
RETURN ON EQUITY
10.0%
NET MARGIN
29.8%
DEBT/EQUITY
0.01
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
99.8%
FLOAT SHARES
61,736,029
AVG. DAILY VOLUME (30D)
368,247
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -3.2%
Search (Google Trends)
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about argenx stock
What does argenx do?
argenx SE is a company in the Healthcare sector, Biotechnology industry, headquartered in Netherlands.
The CEO is Karen Massey, the company employs around 1,863 people.
The IPO was on 18/05/2017; the stock trades on NASDAQ under the ticker ARGX.
What do analysts say about argenx stock?
36 analysts rate the stock, the consensus is Buy (as of 14/10/2026).
The average price target is US$1,138.60, ranging from US$823.00 to US$1,400.00, with a median of US$1,140.00.
This is an external assessment, not a statement by Market Jury.
When does argenx report next?
The next earnings date is 04/03/2027.
Around past earnings, price swings were roughly -9% stronger than usual.
Does argenx pay a dividend?
No, argenx currently does not pay a dividend.
Which stocks are comparable to argenx?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, BeOne Medicines, Incyte, Genmab A/S and Exelixis.
How can I get argenx stock analyzed?
Clicking "Analyze stock" lets five strategies assess argenx against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.